Extracorporeal shockwave lithotripsy and litholytic therapy in cholelithiasis

Br J Surg. 1992 Mar;79(3):235-6. doi: 10.1002/bjs.1800790316.


Extracorporeal shockwave lithotripsy (ESWL) and litholytic therapy were used in 100 patients over a period of 16 months. ESWL was carried out with a Lithostar Plus and chenodeoxycholic acid was used as the lytic agent, given until 3 months after complete disappearance of stones. Within a period of 8-12 months, stones disappeared completely in 82 per cent of the patients who had a single stone less than or equal to 20 mm in diameter and in 50 per cent of those with a single stone greater than 20 mm in size or with multiple stones. Complications requiring surgery developed in five patients: three had acute cholecystitis and two developed acute pancreatitis. Of the patients in whom complete stone clearance was achieved, two of 11 followed up developed recurrence of stones 4 months after cessation of lytic therapy.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Chenodeoxycholic Acid / adverse effects
  • Chenodeoxycholic Acid / therapeutic use*
  • Child
  • Cholelithiasis / therapy*
  • Combined Modality Therapy
  • Female
  • Humans
  • Lithotripsy* / adverse effects
  • Male
  • Middle Aged
  • Recurrence
  • Time Factors


  • Chenodeoxycholic Acid